INTRODUCTION: EXPEDITION and EXPEDITION2 were identically designed 
placebo-controlled phase 3 studies assessing effects of solanezumab, an 
antiamyloid monoclonal antibody binding soluble amyloid-β peptide, on cognitive 
and functional decline over 80 weeks in patients with mild-to-moderate 
Alzheimer's disease (AD). Primary findings for both studies have been published.
METHODS: Secondary analyses of efficacy, biomarker, and safety endpoints in the 
pooled (EXPEDTION + EXPEDITION2) mild AD population were performed.
RESULTS: In the mild AD population, less cognitive and functional decline was 
observed with solanezumab (n = 659) versus placebo (n = 663), measured by 
Alzheimer's Disease Assessment Scale Cognitive subscale, Mini-Mental State 
Examination, and Alzheimer's Disease Cooperative Study-Activities of Daily 
Living functional scale Instrumental ADLs. Baseline-to-endpoint changes did not 
differ between treatment groups for Alzheimer's Disease Cooperative 
Study-Activities of Daily Living functional scale, basic items of the ADCS-ADL, 
and Clinical Dementia Rating Sum of Boxes. Plasma/cerebrospinal fluid biomarker 
findings indicated target engagement by solanezumab. Solanezumab demonstrated 
acceptable safety. Efficacy findings for the moderate AD population are also 
provided.
DISCUSSION: These findings describe solanezumab effects on efficacy/safety 
measures in a mild AD population. Another phase 3 study, EXPEDITION3, will 
investigate solanezumab's effects in a mild AD population.